Israel Englander Biogen Inc. Call Options Transaction History

Millennium Management LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$189.07 - $236.8 $10.6 Million - $13.2 Million	-55,900 Reduced 65.38%	29,600 $5.74 Million
Q2 2024 Aug 14, 2024	BUY	$190.52 - $236.72 $7.79 Million - $9.68 Million	40,900 Added 91.7%	85,500 $19.8 Million
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $1.44 Million - $1.82 Million	6,800 Added 17.99%	44,600 $9.62 Million
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $6.39 Million - $7.69 Million	-28,700 Reduced 43.16%	37,800 $9.78 Million
Q2 2023 Aug 14, 2023	BUY	$275.25 - $318.06 $9.88 Million - $11.4 Million	35,900 Added 117.32%	66,500 $18.9 Million
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $7.62 Million - $8.68 Million	-29,700 Reduced 49.25%	30,600 $8.51 Million
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $16.7 Million - $20.3 Million	-66,300 Reduced 52.37%	60,300 $16.7 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $24.6 Million - $34 Million	126,600 New	126,600 $33.8 Million

1,036

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $22.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.